Milestone Pharmaceuticals (NASDAQ:MIST) CEO Joseph Oliveto Sells 36,500 Shares of Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 36,500 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at $1,008,511.44. This represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joseph Oliveto also recently made the following trade(s):

• On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39.

Milestone Pharmaceuticals Trading Down 2.9%

NASDAQ MIST opened at $2.04 on Tuesday. The company has a market capitalization of $240.05 million, a PE ratio of -2.58 and a beta of 0.69. The company has a fifty day moving average of $1.65 and a 200 day moving average of $1.95. Milestone Pharmaceuticals Inc. has a 1 year low of $0.88 and a 1 year high of $3.06. The company has a debt-to-equity ratio of 1.37, a current ratio of 8.01 and a quick ratio of 7.96.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Friday, March 20th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $37.52 million. Research analysts forecast that Milestone Pharmaceuticals Inc. will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of MIST. Strategic Family Wealth Counselors L.L.C. acquired a new position in Milestone Pharmaceuticals in the 4th quarter valued at $25,000. Sapient Capital LLC acquired a new position in Milestone Pharmaceuticals in the 3rd quarter valued at $25,000. Eaton Financial Holdings Company LLC acquired a new position in Milestone Pharmaceuticals in the 4th quarter valued at $26,000. Bank of America Corp DE raised its stake in Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares during the last quarter. Finally, Stephenson & Company Inc. acquired a new position in Milestone Pharmaceuticals in the 3rd quarter valued at $40,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on MIST. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Raymond James Financial began coverage on Milestone Pharmaceuticals in a report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price target for the company. Zacks Research downgraded Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Milestone Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $7.50.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.